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Background: Exercise is consistently recommended for older adults with knee pain related to osteoarthritis.
However, the effects from exercise are typically small and short-term, likely linked to insufficient individualisation of
the exercise programme and limited attention to supporting exercise adherence over time. The BEEP randomised
trial aims to improve patients’ short and long-term outcomes from exercise. It will test the overall effectiveness and
cost-effectiveness of two physiotherapy-led exercise interventions (Individually Tailored Exercise and Targeted
Exercise Adherence) to improve the individual tailoring of, and adherence to exercise, compared with usual
physiotherapy care.
Methods/design: Based on the learning from a pilot study (ISRCTN 23294263), the BEEP trial is a multi-centre,
pragmatic, parallel group, individually randomised controlled trial, with embedded longitudinal qualitative interviews.
500 adults in primary care, aged 45 years and over with knee pain will be randomised to 1 of 3 treatment groups
delivered by fully trained physiotherapists in up to 6 NHS services. These are: Usual Physiotherapy Care (control
group consisting of up to 4 treatment sessions of advice and exercise), Individually Tailored Exercise (an individualised,
supervised and progressed lower-limb exercise programme) or Targeted Exercise Adherence (supporting patients to
adhere to exercise and to engage in general physical activity over the longer-term). The primary outcomes are pain
and function as measured by the Western Ontario and McMaster Osteoarthritis index. A comprehensive range of
secondary outcomes are also included. Outcomes are measured at 3, 6 (primary outcome time-point), 9, 18 and
36 months. Data on adverse events will also be collected. Semi-structured, qualitative interviews with a subsample
of 30 participants (10 from each treatment group) will be undertaken at two time-points (end of treatment and 12 to
18 months later) and analysed thematically.
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Discussion: This trial will contribute to the evidence base for management of older adults with knee pain attributable
to osteoarthritis in primary care. The findings will have important implications for healthcare commissioners, general
practitioners and physiotherapy service providers and it will inform future education of healthcare practitioners. It may
also serve to delay or prevent some individuals from becoming surgical candidates.
Trial registration: ISRCTN: ISRCTN93634563.
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Knee pain in older adults is a common disabling prob-
lem, managed in the UK mostly in primary care [1].
Osteoarthritis (OA) is the most likely underlying diagno-
sis and refers to a clinical syndrome of joint pain accom-
panied by varying degrees of function limitation and
reduced quality of life [2]. The most commonly affected
peripheral joints are the knees and OA has been shown
by radiography to be present in 70% of community
dwelling adults aged 50 or more with knee pain [3].
Structural changes before radiography are common in
the remainder [4]. Clinical trials and systematic reviews
consistently show the benefit of exercise, in a variety of
forms, for this patient group [5-9]. Exercise improves
muscle dysfunction and reduces pain and disability with-
out exacerbating joint damage [10]. It can reduce the
risk of other chronic conditions [11] and improve the
physical status of people with OA [12,13]. Physiothera-
pists are the largest group of exercise advisors for mus-
culoskeletal problems in the UK National Health Service
(NHS) and are therefore an appropriate group with
which to develop and test strategies to improve out-
comes from exercise with older adults with knee pain.
Previous studies have shown that older adults with knee
pain and physiotherapists involved in their treatment
have concerns about the safety of exercise, do not con-
sider exercise as an effective treatment for pain, do not
focus on issues of exercise adherence and fail to trans-
late traditional lower limb focused exercise into sustain-
able lifestyle changes [14].
The TOPIK trial [15] tested two primary care services
for knee pain in older adults, an enhanced pharmacy re-
view and community physiotherapy (based on advice
and exercise) and compared these with advice and self-
care alone. At 3 months, pain reduction was three times
greater and functional improvement four times greater
in those patients randomised to physiotherapy compared
with advice alone, and more people obtained clinically
meaningful changes [16,17] than those in the other two
groups. Patients received, on average, four physiotherapy
treatment sessions. There was evidence that the benefits
in pain and function declined in the longer-term, sug-
gesting that most patients require some form of moni-
toring or regular access to physiotherapy or exercisesupervision for potential on-going benefit. The APEX
trial [18,19], which incorporated a more intensive exer-
cise intervention that was supervised and progressed
over six treatment sessions, resulted in greater improve-
ments in pain than the exercise programme in the
TOPIK trial [15].
Similarly, other recent trials [20,21] and reviews [22]
showed small to moderate, short-term reductions in
knee pain and disability that are not sustained in the
long-term. Exercise is clearly worth doing but we need
to find out if, and how, the beneficial effects can be en-
hanced and maintained, crucial factors in the manage-
ment of a chronic condition like knee osteoarthritis.
Conversations with patients during telephone follow-ups
in the APEX trial helped to explain why the effects of
exercise might be sub-optimal [19]. Participants reported
misconceptions about exercise in the presence of knee
joint damage and pain, difficulty fitting the exercises into
a daily routine, overly-complex exercise programmes, in-
sufficient tailoring of the exercise programmes for their
individual needs and, in some cases, they simply forgot
to do the exercises.
Reviews highlight a lack of information about how to
optimise exercise for this patient group [6-8]. Most stud-
ies are short-term, use limited measures of adherence
and standardised exercise programmes [23]. Adherence,
independent of exercise type, may be an important fac-
tor in the success of exercise interventions. There is evi-
dence that better adherence to exercise improves pain
relief [21] and disability [23] and that the addition of
booster sessions may be helpful in maintaining positive
effects on pain and function [22]. A UK consensus [24]
identified adherence and tailoring of exercise to individ-
uals as important research topics. In the general physical
activity literature, a Cochrane review concluded that
physical activity programmes that include patient goal
setting, individually tailored and written exercise pro-
grammes, some professional guidance and ongoing sup-
port, may be the most effective approach [25]. In
preparation for the BEEP trial, we conducted two stud-
ies. First, a Cochrane systematic review summarising the
evidence to date about interventions to improve adher-
ence with exercise in patients with chronic musculoskel-
etal pain [26]. Second, the Keele Attitudes and Beliefs
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the exercise attitudes and behaviours of older adults with
knee pain in the community (n = 611) and physiothera-
pists involved in managing older adults with knee pain
(n = 538), to identify potential barriers to, and facilitators
of, exercise for knee pain [14,27-29]. The findings of our
Cochrane review, based on 42 trials with over 8,000 pa-
tients, suggested using a multifaceted programme com-
bining educational and behavioural strategies to enhance
exercise adherence, and incorporating individualisation
of the exercise, follow-up and supervision to improve ex-
ercise adherence [26]. No one theoretical model under-
pinning exercise adherence was shown to be superior
and the interventions that incorporated motivational
strategies showed promise. A subsequent review by Ben-
nell and Hinman [30] stated that the optimal exercise
dosage is yet to be determined and an individualised ap-
proach to exercise prescription is required based on an as-
sessment of impairments, patient preference, co-morbidities
and accessibility. They suggested that maximising adherence
is a key element dictating success of exercise therapy and
that adherence can be enhanced by the use of supervised ex-
ercise sessions in the initial exercise period followed by
home exercises. Bringing patients back for intermittent con-
sultations with the exercise practitioner, or attendance at ‘re-
fresher’ sessions was also suggested to assist long-term
adherence and result in improved patient outcomes. Our
ABC knee study showed that whilst physiotherapists use ad-
vice and exercise routinely for older adults with knee pain,
they do not consider exercise to be an effective treatment
for pain, have worries about its safety, provide care over rela-
tively few treatment sessions thus reducing the capacity to
adequately individualise, supervise and progress the exercise
programme, and do not routinely follow-up patients to
check adherence or to support the translation of lower-limb
focused exercise into sustainable lifestyle changes in physical
activity. Although patients are aware of risk factors (e.g. sed-
entary lifestyles), they find it hard to make and maintain ap-
propriate lifestyle changes and express the desire for more
support from health professionals [14,27-29]. Marks [31] de-
scribes the many factors that influence exercise adherence
in patients with knee OA as either intrinsic (personal factors
like self-efficacy, motivation, age, gender, disease status) or
extrinsic (e.g. environmental, social factors or other lifestyle
issues). These barriers can vary both over time and between
individuals, meaning that one single approach to enhancing
exercise adherence might not be as effective as an individu-
ally tailored approach. The World Health Organisation ad-
vocates an “adherence counseling toolkit” that can be used
to systematically assess barriers and facilitators to adherence,
and suggests that new interventions to enhance adherence
are required [32].
Recent national and international clinical guidelines
[2,24,33] support the overall effectiveness of exercise inknee OA, placing it as a key component of core treat-
ment in primary care. However, there is a lack of evi-
dence around the practical aspects of exercise delivery
and maintenance, including how to support individuals
to continue to exercise in the longer-term. UK guidelines
from the National Institute of Health and Clinical Excel-
lence (NICE) published in 2008 recommended future re-
search should test ways to improve adherence with
exercise [34] and the Chartered Society of Physiotherapy
ranked testing ways to help patients incorporate exercise
behaviours in their everyday life and increase the long-
term effects of exercise as the top musculoskeletal re-
search priority in its national priority setting exercise in
2010 [35].
The Benefits of Effective Exercise for knee Pain (BEEP)
trial is a logical consequence of recent primary care tri-
als, systematic reviews and guidelines for knee pain in
older adults, which consistently support exercise-based
interventions, but highlight the short-term, small to
moderate-sized benefits [2,6]. The overall aim of the
BEEP trial is to test, in older adults with knee pain at-
tributable to OA, whether pain and function outcomes
can be improved through changing the characteristics of
the exercise programme in comparison to usual physiother-
apy care. The research hypotheses are i) a physiotherapy-led
individualised, supervised and progressed lower limb exer-
cise programme is superior to usual physiotherapy care and
ii) a physiotherapy-led intervention targeting exercise adher-
ence in the longer-term and supporting the transition from
lower limb exercise to general lifestyle physical activity is su-
perior to usual physiotherapy care. Secondary objectives are
to compare the cost-effectiveness of the two exercise inter-
ventions compared to usual care and investigate differences
in knee pain-related perceptions and expectations, as well as
exercise adherence and physical activity. A linked qualitative
study exploring participants’ views of the interventions




This is a multi-centre, pragmatic, three-parallel group,
assessor-blind, superiority, individually randomised con-
trolled trial comparing two physiotherapy-led exercise-
based interventions versus usual physiotherapy care, with
embedded qualitative interviews with a subsample of par-
ticipants. In preparation for this trial, we conducted a
small pilot study in two NHS Primary Care Trusts (PCTs)
to investigate the feasibility of training physiotherapists in
the new treatment approaches, the acceptability of the
treatments to patients and physiotherapists and to test the
processes for the main trial.
For the main trial, participants are randomised (inde-
pendently) at each treatment site with block randomisation
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ally tailored exercise (ITE) and targeted exercise adherence
(TEA). 500 participants will be recruited over a period of
18 months. Each participant’s involvement with the trial is
for 36 months, during which time they will all have access
to usual primary care. The primary outcome is assessed
6 months from randomisation, but no analyses will be
undertaken until the 18 month follow-up time-point.
Setting
Participants are recruited from up to 100 general prac-
tices and their local physiotherapy services in the West
Midlands and North West regions of the UK. Treat-
ments are delivered within physiotherapy centres in up
to 6 NHS Primary Care Trusts (PCTs) within the geo-
graphical regions of the Primary Care Research Network
(PCRN) of the West Midlands North and the North
West. The practices and treatment centres include a mix
of urban/suburban/semi-rural/rural settings.
Participants
Participants are eligible for inclusion if they are 45 years
old and over, have current knee pain and/or stiffness in
one or both knees, are able to read and write in English,
are willing to participate, are able to give full informed
written consent and have access to a telephone (for
minimum data collection). We are deliberately choosing
not to restrict the BEEP trial to people with radiograph-
ically diagnosed knee OA in order to reflect current clinical
practice and national guidance [2] in which treatment
choices are made on the basis of symptoms rather than on
radiographic findings. We are thus including people typical
of those seen in primary care. Patients recruited through the
population survey and the record reviews at participating
general practices will have a Chronic Pain Grade [36] sever-
ity of between 2 to 4, determined through a brief postal
screening survey. This is to ensure that participants will have
a mean level of pain and functional difficulty similar to those
patients referred to physiotherapy (determined from our
previous trials [15,19] and that the interventions will be suit-
able for such patients. Chronic Pain Grade 2 to 4 categories
have also been reported as a clinically significant group of
knee pain patients in other research studies [36-38].
Exclusion criteria are as follows: those with potentially ser-
ious pathology (such as inflammatory arthritis, malignancy),
those who have had a total hip or knee replacement on the
affected side, those who are on a waiting list for a total knee
or hip replacement, those for whom their knee problem was
caused by a recent trauma (sports injury, fall or accident),
those for whom exercise interventions are contra-indicated
(such as those with unstable cardiovascular disorders, severe
hypertension, unstable angina or congestive heart failure),
those who have received an exercise programme from a
physiotherapist or a knee joint injection in the last threemonths, those residing in nursing home accommodation,
those who are so severely physically restricted that they can-
not get to the physiotherapy treatment centres and those
who have a close family member already participating in the
BEEP trial. Normal recreational involvement in physical ac-
tivity will not be an exclusion criterion.
Invitation, recruitment, consent and randomisation
Identification of potentially eligible participants
The key learning from the pilot study which recruited
participants only from those patients who were already
referred by their General Practitioner (GP) to physio-
therapy services was the need to increase recruitment to
identify all potentially eligible participants. Therefore, in
the main BEEP trial participants will be identified in one
of three ways: (1) from general practice computer record
reviews to identify those who have consulted for knee
pain in the last 12 months, (2) from a population survey
of older adults registered with participating practices
and (3) from patients referred from their general prac-
tice to physiotherapy services for knee pain. These will
proceed in parallel and are described in more detail
below. Duplication checks will ensure that eligible partici-
pants are not invited to the BEEP trial more than once.
See Figure 1 for a summary flowchart of the methods to
identify and recruit participants.
(1) General Practice record review: Members of the
Primary Care Research Network (PCRN)
informatics team contracted to work in the
participating general practices will screen computer
records, for adults aged 45 years and over who
have consulted with knee pain in the last
12 months at the practice. The electronic screen
will identify patients based on the 14 most frequent
knee pain related Read codes that have been
informed by our previous research [39]. Read codes
are the standard clinical terminology system that
GPs enter onto their computer systems in the UK,
identifying patients’ clinical symptoms and
diagnosis. In addition, the electronic screening
protocol will exclude those with potentially serious
pathology (e.g. inflammatory arthritis such as
rheumatoid arthritis, malignancy etc) and those in
nursing home accommodation. GP’s will be invited
to screen the sample list and exclude those patients
whom they consider inappropriate to be invited to
participate in the trial. PCRN staff will then
administer the mailing of a short screening
questionnaire to check eligibility and determine the
patient’s Chronic Pain Grade classification [36].
Patients recruited through this method must have
a Chronic Pain Grade severity of between 2 to 4.
The final section of the brief screening
Figure 1 Flow diagram summarising participant recruitment in the BEEP trial.
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be happy to give their consent for further contact.
Patients will return their screening questionnaires
to the Arthritis Research UK Primary Care Centre
and only those who are eligible and consent to
further contact will form the sample that is sent
information about the BEEP trial.
(2) Population survey: Older adults (aged 45 years
and over) registered with participating general
practices will be mailed with a short screening
questionnaire to identify potentially eligible trial
participants. GP’s will be invited to screen the
mailing list and exclude those patients whom they
consider inappropriate to be invited to participate
in the trial. This screen will be used to identify
those in the community with knee pain of
sufficient severity [36] to be included in the BEEP
trial, and to exclude those who do not meet the
eligibility criteria. Patients recruited through this
method must have a Chronic Pain Grade severity
of between 2 to 4. The final section of the brief
screening questionnaire will ask older adultsregistered with the practice whether they would be
happy to give their consent for further contact.
Those who are eligible and consent to further
contact will form the sample that is sent
information about the BEEP trial.
(3) Physiotherapy service referrals: Older adults with
knee pain referred by their GP or who self refer to
participating physiotherapy services will be first
screened, by a member of the physiotherapy service
team, for key eligibility criteria (aged 45 years and
over, with knee pain and/or stiffness). Those that are
potentially eligible will be contacted by a PCRN
research nurse to find out if they are willing to
receive further information about the BEEP trial.
The three recruitment methods will proceed in parallel
until the sample size required is reached, although methods
1 and 2 will be operationalised in different GP practices.
Recruitment and consent of participants to the BEEP trial
From identification methods (1), (2) and (3) above, those
who meet the eligibility criteria and who agree to further
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(a cover letter, a participant information sheet (PIS) (See
Additional file 1 for a copy of the PIS), a baseline ques-
tionnaire, a consent form and a freepost return enve-
lope). No less than 48 hours after receiving the posted
information, a PCRN nurse will telephone the person to
further check and confirm eligibility. This check will
cover the full eligibility criteria in order to ensure that
only those who meet these criteria are then recruited to
the trial. In addition, the nurse will screen out individ-
uals with known unstable cardiovascular disorders and
those who have such severely restricted mobility that
they would not be able to get to the physiotherapy
clinics for treatment. All potentially eligible participants
will have the opportunity to discuss the trial with the re-
search nurse prior to deciding whether or not to partici-
pate. Those who wish to take part in the trial will be
asked to sign and date the written consent form, sup-
ported by the research nurse over the telephone, and re-
turn it along with their completed baseline questionnaire
to the nurse in a pre-paid envelope. Those who do not
wish to take part will be asked to indicate this on the con-
sent form and to return it to the nurse in the pre-paid en-
velope provided. This consent process was tested in the
pilot study and regular audits of the nurse telephone calls
will form part of the quality assurance procedures of the
BEEP trial. It is possible, based on this consent method,
that a very small number of participants in the BEEP trial
will be found to be subsequently ineligible since it is only
after consent that participants have a detailed physical as-
sessment by a BEEP trial physiotherapist. Examples of this
are expected to include a very small number of partici-
pants who have radiating leg pain from a spinal problem
or a hip joint problem with referred pain in the area of the
knee.
Participating general practices will be supported to as-
sist with identification of potentially eligible participants
for the BEEP trial through small practice payments to
reimburse their time for screening patient lists and
physiotherapy services will be supported to participate
through financial reimbursement for the time taken out
from service delivery for the training programme and
additional time for BEEP treatments. Participants will
not receive any financial incentives to return screening
questionnaires, to take part in the trial or to return their
follow-up questionnaires.
Randomisation and allocation concealment
Following receipt of a signed consent form and baseline
questionnaire, the BEEP trial administrator will random-
ise the participant using a computer-generated randomisa-
tion schedule provided by the Musculoskeletal Clinical
Trials Unit (CTU) at Keele University, password-protected
to ensure that research nurses and trial statisticians remainblind to treatment allocation. Participants will be individu-
ally randomised to one of the three treatment groups using
random permuted blocks of size 3. To ensure that patients
at each physiotherapy clinic have a chance of receiving any
of the interventions, randomisation will be stratified by
physiotherapy clinic. Following randomisation, the trial
co-ordinator will liaise with the appropriate physio-
therapy clinic to arrange the first appointment for each
trial participant. The patient will then be informed in
writing of the date, time and location of their first ap-
pointment in the physiotherapy clinic. The GP of each
trial participant will be sent a letter to confirm that
their patient is taking part in the BEEP trial. Thus our
procedures ensure baseline data are collected prior to
randomisation, that the allocation is concealed until
after the patient has been recruited into the trial and
until the moment of randomisation and that the person
assigning participants to intervention groups (study ad-
ministrator) has no involvement in the eligibility screen,
consent or treatment processes.
Sources of bias
Selection bias at recruitment will be avoided by separat-
ing the processes of determining patient eligibility and
treatment allocation and by using random permuted
blocks overseen by the CTU, not allowing physiothera-
pists assessing and treating patients to predict the next
allocation in their clinic. Trial participants will know
they are having physiotherapy-led exercise and brief de-
tails about the three interventions (see Additional file 1
PIS). It is not possible to blind physiotherapists but they
will deliver treatment to participants in only one of the
three intervention groups. A PCRN nurse blind to treat-
ment allocation will obtain informed consent and
oversee the collection of baseline and follow-up ques-
tionnaire data, and will collect minimum data over the
telephone where necessary. An evaluation of the suc-
cess of nurse blinding procedures will be completed
and a procedure for reporting incidents where blinding
has been compromised will be in place.
Data entry, coding, security, storage and management
will follow the standard operating procedures in the
CTU at Keele University. Data enterers will receive
training in line with CTU procedures and will be blind
to the identification of the three intervention groups.
Random 10% data entry accuracy checks will be con-
ducted at regular intervals, data accuracy will be audited
and accuracy rates recorded. The trial statistician (EN)
will remain blind until after the creation of a locked ana-
lysis dataset at 18 months follow-up and the completion
of the primary and secondary analyses.
Comparing available variables between consenting and
non-consenting individuals, trial participant withdrawals
and completers will be carried out to evaluate external
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the trial at any time without having to give any explan-
ation. Where possible, we will collect information about
the reasons for withdrawal from the trial. Using vali-
dated outcome measures will reduce measurement
error. Treatment will be recorded by physiotherapists
in standardised formats and audits of these case report
forms will be undertaken throughout. Feedback to
physiotherapists delivering the interventions will be
provided, where necessary, so they can modify and im-
prove the delivery of the interventions. Each interven-
tion is supported by a specific protocol and documentation,
developed for the BEEP trial and previously tested in the
pilot study.
Interventions
The interventions will be delivered in participating physio-
therapy centres in up to 6 NHS Primary Care Trusts
(PCTs). All patients will receive an advice and information
booklet (which will include information about the value of
specific lower limb and general exercise and simple self-
help messages such as the use of analgesics, and home
heat therapy for pain relief, see Additional file 2 for a copy
of the advice booklet) and a home exercise programme.
Different physiotherapists delivered each of the three in-
terventions. Each of the three intervention groups are de-
tailed below with supporting explanation and justification
(see Table 1 for a summary of the interventions). They are
all examples of complex interventions as they involve a
number of separate but interacting components that are
likely to be important to the success of the intervention
[40]. Whilst the key outcomes are knee pain and disability,
the interventions are all behaviour change interventionsTable 1 Summary of the BEEP trial interventions
Key features Usual physiotherapy care Individually tailored ex
Number of
sessions
Up to 4 sessions 6 to 8 sessions
Time period of
treatment





Advice and information b
Exercise focus Focus on lower limb
exercise
Focus on lower limb exer




patient, supported by an
written exercise program
Progression Minimal progression Good progression
Supervision Minimal supervision Good supervision
Exercise
monitoring





No follow-up after 12 wefocused on exercise and physical activity behaviour
change.
All participants may continue to access usual primary
care in addition to BEEP treatment. This may include
ongoing or new medications, further healthcare consul-
tations with other health professionals, referrals for im-
aging and surgical opinion and these co-interventions
will be recorded on participants’ follow-up question-
naires. For the purposes of the trial, physiotherapy ser-
vices will contact participants who fail to attend their
treatment sessions up to three times in order to try to
(re)engage the participant in BEEP treatment sessions.
Hydrotherapy, group-based sessions, acupuncture and
intra-articular injections will not be permitted in any of
the BEEP trial treatment protocols. Intervention fidelity
will be assessed through audits of treatment data col-
lected in trial-specific case report forms (comparing
these data with the intervention protocol and with the
physiotherapy clinical records). We will collect data on
the number and content of BEEP treatment sessions
using physiotherapy case report forms in all three treat-
ment groups and use those data in our interpretation of
the trial results.
Intervention 1: usual physiotherapy care
Usual physiotherapy care consisting of advice and exer-
cise is the most appropriate control group for the BEEP
trial given that randomised trials [15] and systematic re-
views [6] consistently show that interventions that in-
clude exercise are superior to those which do not. We
are not using an attention control group as this trial is
designed explicitly as a pragmatic trial, building on evi-
dence about the effectiveness of exercise interventions.ercise Targeted exercise adherence
8 to 10 sessions
Up to 6 months
ooklet Advice and information booklet
cise Focus on both lower limb and general exercise.
Signposting and support to engage in general




Exercises individually prescribed for each patient,




Exercise and physical activity diaries
eks Follow-up and monitoring contacts (telephone or face
to face) through to 6 months
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tients with OA are advised to exercise and in UK clinical
practice, patients are seen in relatively few treatment
sessions, and provided with brief relatively standardised
exercise programmes that do not take into account dif-
ferences between individual patients. Our ABC knee
study described usual UK physiotherapy practice and
formed the basis for the BEEP trial protocol for usual
care [14].
The BEEP trial protocol for usual physiotherapy care
will consist of advice and lower limb exercise previously
tested and shown to be more effective in the short-term
than advice alone [15]. Exercises will be selected from
an agreed template of commonly prescribed exercises
(printed from the commonly used PhysioTools com-
puter software), including specific lower limb muscle
strengthening (non-weight-bearing and weight-bearing)
and range of movement or stretching exercises. Patients
will receive up to 4 one-to-one treatment sessions with a
physiotherapist over a period of 12 weeks, during which
advice to continue to exercise will be provided but indi-
vidualisation, progression and supervision of the exercise
programme will be minimal, as in usual care. Other inter-
ventions used frequently by physiotherapists such as man-
ual therapy and electrotherapy will be permitted as per
usual care and they will be recorded on case report forms
but the emphasis of the intervention will be supporting
the patient to self-care and to follow the advice and ex-
ercise programme at home. This usual care protocol
matches usual UK practice in that it focuses on lower
limb strengthening exercise, relies on self-report rather
than the use of exercise diaries to monitor adherence
and progress, is delivered over few treatment sessions
and thus has limited opportunity for individualisation,
supervision or exercise progression and does not offer
refresher or booster sessions following the end of the
episode of care [14].
Intervention 2: individually tailored exercise (ITE)
Standardised exercise programmes such as those used in
the usual physiotherapy care group in the BEEP trial do
not take into account differences between individual pa-
tients. Consequently, individuals will be working at rela-
tively different intensities, which for some may be too
little to get a training effect, and for others may be too
difficult. To be optimally beneficial, exercise should be
progressed so that appropriate physical stress is placed
upon the individual for further improvements to be ob-
tained [40]. Exercise self-efficacy (confidence to exercise
despite the knee pain) has been identified as a predictor of
exercise behaviour in many populations [41,42]. Supervi-
sion of exercise can enhance patients exercise self-efficacy
and self-regulatory skills and reassure them that they can
perform the exercises. It also provides good opportunityto reassure the patient about pain responses to specific ex-
ercises or to change the exercise prescription to ensure
optimal performance or more tolerable pain response.
Lack of adequate individual tailoring, supervision and pro-
gression of the lower limb exercise programme may in
part explain the small benefits seen in some previous exer-
cise trials. Our previous trial results [15,19] suggested that
a lower limb exercise programme that was supervised and
progressed over six treatment sessions resulted in greater
improvements in pain than one provided over an average
of four sessions. Therefore the protocol for Individually
Tailored Exercise was developed to ensure the prescrip-
tion of an individualised, supervised and progressed lower
limb exercise programme.
The BEEP trial protocol for Individually Tailored Exer-
cise will consist of a supervised individually tailored and
progressed exercise programme. The aim of the inter-
vention is to initiate and progress an individually tailored
exercise programme, which is supervised in clinic, prac-
ticed at home and progressed in terms of intensity over
12 weeks. The intervention is modelled on a previously
successful exercise intervention from one of our previ-
ous trials [19], and focuses on individualised strengthen-
ing (non-weight-bearing and weight-bearing), stretching
and balance exercise for lower limb rehabilitation and
functional task training. The patient and physiotherapist
will define lower limb functional and exercise goals and
agree targets that are reviewed and progressed. Individu-
alisation is based on the findings of the physiotherapy
assessment of each individual, including biomechanical
and physiological observations, pain responses to spe-
cific exercises and starting levels of strength, range of
movement and balance. Exercises will be prescribed for
each individual and participants will be given their own
individual print-out of their specific exercise prescription
(selected and printed from PhysioTools computer software)
and these exercise prescriptions (and print-out instructions)
will change over time as the exercise programme is pro-
gressed. Physiotherapists will encourage exercise behaviour
change using self-monitoring through use of an exercise
diary to record their adherence with their lower limb exer-
cise prescription (see Additional file 3). In order to provide
greater opportunity for individualisation, supervision and
progression of exercise, patients will receive between 6 to 8
one-to-one treatment sessions with a physiotherapist.
There will be no scheduled follow-ups (refresher or booster
sessions) with the physiotherapist beyond 12 weeks.
Intervention 3: targeted exercise adherence (TEA)
Adherence to long-term treatment regimes, particularly
those involving behavioural components such as exer-
cise, is consistently lower than adherence to medication
[43]. Exercise adherence, irrespective of exercise type,
may be a key factor determining the success of exercise.
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we observed high exercise adherence rates in the short-
term through to the end of treatment at 12 weeks, which
fell to just over 50% at 12 months [19]. Long-term ad-
herence to lower limb exercise is perhaps unrealistic as
these can be challenging to incorporate into daily rou-
tines and individual lifestyles and many patients do not
consider them enjoyable, stopping them once symptoms
reduce or resolve. It may be more realistic to target gen-
eral physical activities that individuals have previously
engaged in and enjoyed (since previous exercise behav-
iour is theoretically the strongest source of self-efficacy
information [41], or physical activities that individuals
have positive expectations about (since these positive ex-
pectations may increase exercise intentions and ultimately
exercise behaviour) in order to support engagement in
and adherence to exercise. Our previous ABC knee study
[28] highlighted the many different barriers and facilitators
to exercise and physical activity, and that no single exer-
cise type or exercise setting is acceptable to all. Thus we
designed this Targeted Exercise Adherence intervention to
include an adherence-enhancing ‘toolkit’ of optional tools
and techniques for physiotherapists to use with different
participants, based on their assessment of individual
participants and early feedback from participants (See
Additional file 4 for summary of contents of the tool-
kit). The content of the intervention was directly in-
formed by the results of our Cochrane systematic
review [26] and a networking meeting, supported by
Arthritis Research UK, during which national experts
and patient advocates agreed the intervention. Whilst
the general physical activity identified and encouraged
by physiotherapists will be individualised for partici-
pants, we anticipate that many may choose walking as
it is seen as inexpensive and accessible. Pedometers
have been shown to increase physical activity [44] and
to increase step counts in older people [45] and there-
fore we will include pedometers within the suite of op-
tions for physiotherapists to give participants who wish
to target increases in walking activity.
The BEEP trial protocol for Targeted Exercise Adher-
ence will begin with a focus on the lower limb (as in the
Individually Tailored Exercise group) but transitions to
focus increasingly on general physical activity adherence
over time. In addition to prescribing an individualised,
progressed and supervised lower limb exercise programme,
physiotherapists will assess patients’ current general phys-
ical activity levels, their intentions to increase their physical
activity levels, their attitudes to exercise for knee pain and
general health and explore their individual barriers and po-
tential facilitators to exercise. This group will receive 4
treatments up to week 12 and a further 4 to 6 contacts
from week 12 through to 6 months (a total of 8 to 10 treat-
ment contacts). In the first 4 treatments, the aim will befor participants to initiate and progress an exercise
programme with supervision that will include lower
limb and general exercise, and to identify (with the
support of the physiotherapist) general physical activity
opportunities within the local community that are suit-
able for, and interest, the individual. Pro-active follow-
up from the physiotherapist will take place from week
12 through to 6 months, using choices of telephone
and face-to-face contact, providing an additional 4 to 5
contacts with each participant. The aim is to enhance
long-term exercise adherence, promote increased gen-
eral physical activity and encourage participants to de-
velop an exercise ‘habit’, shifting the focus away from
lower limb exercise in the earlier treatment sessions
and towards sustainable lifestyle changes in physical activ-
ity in later treatment sessions. The follow-up sessions will
ascertain and promote exercise adherence, increases in
physical activity levels, support patients to integrate exer-
cises into their activities of daily living, allow repetition
and amendment of the exercise programme based on indi-
viduals’ experiences or concerns and progression at a pace
suitable for the individual. The adherence enhancing ‘tool-
kit’ contains different educational and behavioural tools
for facilitating physical activity behaviour change, selected
for use based on an individualised assessment of each pa-
tient. As our Cochrane review identified that no one
model of behaviour change was superior for facilitating
adherence to exercise for chronic musculoskeletal pain,
different theoretical models have underpinned the devel-
opment of the toolkit, including self-efficacy [42] and self-
regulation theory [46]. Tools will include self-monitoring
through use of exercise and physical activity diaries
(See Additional file 5), SMART goal-setting (specific,
measurable, achievable, realistic, time-related) to facilitate
the translation of intention into physical activity behaviour,
reminders, corrective feedback and reinforcement, behav-
ioural contracting for physical activity [47], pedometers to
support increases in walking, example templates to discuss
and generate an individual exercise set-back plan, and infor-
mation about (with active support to access) local physical
activity opportunities and facilities in the community. The
target by the end of the 6 months period is that participants
are engaged in physical activity opportunities within their lo-
cality and have had support from the physiotherapist to
overcome initial problems or barriers in engaging in these
activities. The emphasis is therefore on maintenance of
physical activity beyond the period of support from a health
professional and NHS-based programme.
Physiotherapists delivering the interventions
Up to 50 physiotherapists in the participating services
will be trained and supported to deliver one of the three
BEEP trial interventions. A training programme has
been developed and tested in the pilot study and consists
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delivering usual care will attend the first day only, those
delivering Individually Tailored Exercise will attend the
first day plus a further two days of training (total of
three days of training) and those delivering Targeted
Exercise Adherence will attend the first three days plus a
further two days (total of five days of training). On-going
support to adhere to the treatment protocols will be of-
fered through PCRN physiotherapy research facilitators
who have also undertaken the BEEP training programme
and who will conduct regular audits of physiotherapy
case report forms to investigate treatment fidelity. All
physiotherapists will be invited to evaluate the training
programme through completion of brief questionnaires
before and directly following their training and at the
end of treatment of all BEEP trial participants (approxi-
mately 18 months later). Further workshop refresher
sessions to support BEEP physiotherapists will be pro-
vided during the course of the trial. The full details of the
content and justification for the training programme and
the observed changes in physiotherapists’ attitudes, beliefs
and intended behaviours through the use of case vignettes
will be provided in full in a separate publication.
Outcome measures
Primary outcomes
This trial has two primary outcomes, lower limb pain
and function measured using the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC)
[48], collected at baseline and all follow-up time-points (3,
6, 9, 18 and 36 months). The primary time-point is
6 months after randomisation. The psychometric proper-
ties of the WOMAC [48] have been extensively studied in
knee pain populations in clinical trials of different inter-
ventions including exercise [49] and the WOMAC has
been recently shown to be the most responsive of five pain
measures [50]. The pain subscale ranges from 0 (no pain)
to 20 (maximum pain) and the function subscale ranges
from 0 (no disability) to 68 (maximum disability). It is par-
ticularly suitable for the BEEP trial as it specifically cap-
tures self-reported pain during activities and the degree of
difficulty with everyday physical activities, both of which
are key treatment targets of physiotherapy-led exercise.
Secondary outcomes
A range of secondary outcomes will be collected: the
proportion of treatment responders using the inter-
nationally agreed Outcome Measures in Rheumatology
Clinical Trials (OMERACT-OARSI) clinical responder
criteria [16,17] that combines data on pain and function
from the WOMAC [48] with patient’s global assessment
of change (recorded using a 6 point Likert Scale); phys-
ical activity levels (Physical Activity Scale for the Elderly
(PASE) which assesses physical activity levels over a1-week period combining physical activity from several do-
mains including household, occupational and leisure [51]);
self-reported body mass index (calculated from self-reported
height and weight); exercise adherence (attendance at treat-
ment sessions, self-reported adherence to prescribed exer-
cise programme); use of local physical activity facilities in
the previous 7 days (single item); a modified version of a
measure of treatment acceptability and credibility [52,53]; a
measure of illness perceptions (Brief Illness Perceptions
Questionnaire [54]); confidence in ability to exercise (Self-
efficacy for Exercise Scale [55]); outcome expectations from
exercise (Outcome Expectations for Exercise Scale 2 [56]);
anxiety (Generalised Anxiety Disorder Assessment 7 [57]);
depression (Personal Health Questionnaire Depression Scale
[58]); self-reported health care resource use (both NHS and
private health care); and overall health status (EQ-5D-3 L
[59]). Resource use and EQ-5D-3 L data will be used in the
cost-utility analysis (further details are provided in the
‘Economic analysis’ section).
Accelerometry outcomes
Physical activity will also be measured in a subsample of
participants (a target of n = 30 from each group),
through snap-shots of 7-day accelerometry at each
follow-up time-point. Accelerometers are motion sen-
sors worn on the hip and will be used in this trial to esti-
mate physical activity as counts per minute, time spent
in light, moderate and vigorous physical activity and
proportions of people who meet guideline levels of phys-
ical activity [60]. Accelerometers will be allocated at the
point of randomisation. The accelerometer units will be
posted out to the participants with full instructions. Par-
ticipants will be asked to wear the unit during waking
hours for 7 consecutive days and then to post the unit
back to the research centre where the data collected will
be downloaded and analysed. During the trial, accelerome-
ters will be allocated at regular intervals (approximately
monthly) to the next three participants randomised to
each treatment group. A random allocation procedure will
not be used, as not all participants will be willing to wear
them. A regular accelerometer allocation procedure is
needed to enable accelerometers to be available to collect
data for all 90 participants (at baseline and follow-up)
from a pool of 30 accelerometers available for the trial.
The allocation procedure will be phased in at the start of
the trial to ensure that the system is running smoothly
and that accelerometers are being returned in time to be
reused by other participants. Those who do not return
their accelerometers will be posted a written reminder.
Follow-up
Outcome measures will be collected by self-report, postal
questionnaire before randomisation and at 3, 6, 9, 18 and
36 months (Figure 1). Therefore, adherence to exercise
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6 months) and three times during the maintenance phase
of the exercise interventions (9 to 36 months). Non-
responders will be followed up using our standardised
CTU follow-up procedures for trials. This comprises a
questionnaire, a reminder postcard at two weeks and a
further copy of the questionnaire at four weeks. For par-
ticipants who do not respond to any of these reminders,
we will aim to collect minimum outcome measure data
via telephone (by research nurses who are blind to treat-
ment allocation) and post at key outcome time-points
(6 months, 18 months and 36 months) in order to try to
capture primary outcome data and to minimise missing
data. Quality assurance processes within the CTU will en-
sure training and auditing of the research nurses conduct-
ing minimum data telephone calls. In order to reduce
participant burden the 3 and 9 month questionnaires will
be slightly shorter than those at 6, 18 and 36 months and
as direct measures of physical activity may themselves in-
crease physical activity similar measures of physical activ-
ity will be used in each intervention group. Table 2
includes a list of all measures and the time-points at which
they will be collected.
Adverse events
The occurrence of adverse events from all interventions
will be monitored and assessed using case report forms,
contact with the trial co-ordinator, physiotherapist re-
port, and follow-up questionnaires. A common adverse
event from unaccustomed exercise and physical activity
is temporary, mild muscle soreness. Physiotherapists de-
livering the interventions will advise participants about
how to manage such symptoms.
Each physiotherapy site will report any serious adverse
event (SAE) experienced by a trial participant immedi-
ately to the trial Chief Investigator that may possibly be
related to either the interventions or the trial proce-
dures. The Chief Investigator will assess whether the
event was related to or resulted from any of the BEEP
trial interventions or procedures, according to the
process laid out in the BEEP trial Standard Operating
Procedure for SAEs. Any SAE considered to be related
to the trial procedures or interventions will be reported
to the main Research Ethics Committee by the Chief
Investigator within 15 days of her becoming aware of
the event. In addition, all such events will be reported to
the trial sponsor, Trial Steering Committee and Data
Monitoring Committee.
Other data
Other variables collected in participant questionnaires
are age, gender, marital status, co-morbidities, pain loca-
tion using a pain manikin, duration of the knee problem,
experience of exercise and work status.The following process data will also be recorded from
the physiotherapy case report forms: number of treat-
ment sessions attended, the main content of each treat-
ment, physiotherapists contact time with participants,
the number of treatment withdrawals and treatment
non-attendances (DNAs).
Sample size
The sample size for the main trial will be based on the pri-
mary outcome measures: WOMAC pain and function sub-
scales [48] and will compare 6 months post-randomisation
outcome for the usual care group with either of the two
other intervention groups. We chose 6 months since our
TOPIK trial [15] showed the effects of exercise had re-
duced by this point with usual physiotherapy care. The
BEEP trial is powered to detect an effect size of 0.35 for
both WOMAC pain and function; an effect size classified
as ‘small’ to ‘moderate’ using standard benchmarks by
Cohen [61]. We chose to power the trial based on a speci-
fied effect size (rather than minimum important change) as
Terwee et al 2009 [62] report a lack of consensus as to
minimum important change on the WOMAC. From our
previous trials [19], we estimate that the standard deviation
for WOMAC pain and WOMAC function at 6 months
follow-up will be 5 and 17 respectively. An effect size of
0.35 therefore equates to a 1.75 point difference on
WOMAC pain and a 5.95 point difference on WOMAC
function. To achieve 80% power and a 5% significance level
(two tailed) we require 129 patients per treatment group,
giving a total sample of 387 patients [63]. Allowing for a
20% loss to follow-up rate (informed by our previous knee
pain trials [15,19]) we aim to randomise a total of 500 par-
ticipants to the trial over a period of 18 months.
For practical reasons, the sample size will not be in-
flated to allow for clustering of individual patients being
treated by the same physiotherapist [64,65], but rather
the trial will provide useful estimates of clustering effects
and we will adjust for therapists in a sensitivity analysis.
It is anticipated that a minimum of 36 physiotherapists
(12 per treatment group) will be trained to deliver the
trial treatments and that each physiotherapist will treat
approximately 18 patients. Thus at the end of the trial,
we will be able to estimate an intra-class correlation
(ICC) to inform future similar trials.
A formal power calculation was not completed to deter-
mine the number of patients to wear an accelerometer.
The sample size of 30 per group is based on practical con-
siderations (restricted by the number of accelerometers
available for data collection) and on having a reasonable
sample size to analyse the data using parametric statistics.
Embedded qualitative interviews
Qualitative methods have an important role to play in
evaluating complex interventions [66] and in helping to
Table 2 Outcome measures





Weight Stones and lbs or Kilograms 0,3,6,9,18,36
Height Feet and inches or centimeters 0
Marital status Married/separated/divorced/widowed/cohabiting/single 0
Work factors
Current/most recent job title Free Text 0,6,18,36
Currently in a paid Job Yes/No 0,6,18,36
Working hours Working full time (30 hours or more per week)/working part
time (29 hours or less per week)/
6,18,36
Time off because of knee pain including time
off to visit any health care professional
Yes/No (during last 6 months) 6,18,36
How many days weeks, weeks or months were
you absent from work due to knee problem
Number of days/weeks/months (during last 6 months) 6,18,36
Knee Problem
Knee with most discomfort Tick boxes for left or right 0,3,6,9,18,36
Duration of knee problem In the last 12 months/More than 1 year but less than 5 years
ago/More than 5 years but less than 10 years ago/I have had
this knee problem for more than 10 years
0
Global assessment of change in knee problem Completely recovered/much better/better/no change/worse/much











- Personal control 0-10




- Emotional response 0-10
(IPQ-brief modified for knee pain [54])
Physical Activity & Exercise
Experience of exercise Personal experiences of exercise 0
Use of local facilitiesα Use of local facilities for physical activity in the last 7 days 0,3,6,9,18,36
Self-efficacy for exerciseα 0-10 (SSE scale [55]) 0,3,6
Outcome expectations for exerciseα 1-5 (OEE-2 [56]) 0,3,6
Physical activityα 0-400+ (PASE [51]) 0,3,6,9,18,36
Exercise adherence and treatment credibility Confidence in and adherence to treatment plan 3,6,9,18,36
Accelerometryα Average counts per minute For a sub-sample
of participants
0,3,6,9,18,36Meeting physical activity guidelines [60]
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Table 2 Outcome measures (Continued)
General health and well being
Depressionα 0-24 (PHQ8 [58]) 0,3,6,18,36
Anxietyα 0-21 (GAD7 [57]) 0,3,6,18,36
Quality of lifeα -0.59-1 (EQ-5D-3 L [59]) 0,3,6,9,18,36
Body manikin (pain) Body area shaded to represent pain last a day or longer in the last
4 weeks
0
Co-morbidity Tick boxes for key co-morbidities 0
Managing your knee problem
Current medication for knee problem Prescribed and over the counter medications (with dosage and length
of supply)
0,3
Prescribed medication for knee problem Prescribed medications in the last 6 months/12 months/18 months
(with dosage and length of supply)
6,18,36
Cost of over the counter
treatments/appliances
e.g. painkillers, anti-inflammatory drugs, TENS machine, hot and cold
packs, knee supports (£ in the last 6 months/12 months/18 months)
6,18,36
Costs for use of local facilities/opportunities
involving physical activity
(£ in the last 6 months/12 months/18 months) 6,18,36
Healthcare Utilisation Contact with NHS and private healthcare professionals, number of
visits/inpatient stays, types of investigations/treatments in the last
6 months/12 months/18 months
6,18,36
Key: EQ-5D-3 L = Quality of Life; GAD 7 = Generalized Anxiety Disorder 7; IPQ – Brief = The Brief Illness Perception Questionnaire; OEE-2 = Outcome Expectations for
Exercise Scale - 2; PASE = Physical Activity Scale for the Elderly; PHQ8 = Patient Health Questionnaire 8; SEE = Self-Efficacy for Exercise Scale; WOMAC = Western
Ontario and McMaster Universities Arthritis Index. α = Measure used as an outcome to test for clinical effectiveness (along with Body mass index (BMI) and
the OMERACT-OARSI responder criteria [16,17], which are not indicated on this table as derived by combining individual measures of height and weight for
BMI and WOMAC pain and function with global assessment of change for the OMERACT-OARSI responder criteria).
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trial embedded, longitudinal, qualitative interviews will
explore participants’ experiences of treatment, their
views of the acceptability of each intervention, the im-
pact of the interventions on participants' exercise and
general physical activity behaviour and the explanations
for change in knee symptoms and exercise behaviour
over time. Topic guides will include questions that ex-
plore participants’ views of their physiotherapy treat-
ment, how they got on with their exercise programme
and what factors they felt helped or hindered them to
adhere to the exercises following the end of their treat-
ment contact with the physiotherapist, and approxi-
mately 12 to 18 months later. We will also ask what they
feel the future holds for their knee problem. Interviews
will be semi-structured, face to face and will last up to
one hour. Interviews will be longitudinal in that they will
be conducted following physiotherapy treatment com-
pletion, and also in the longer-term 12 to 18 months
later (timed to be after their 18 month BEEP follow-up
questionnaire). The number invited will be determined
by ongoing data analysis and theme saturation but it is
anticipated to continue until approximately 30 sets of
longitudinal interviews have been conducted. Purposive
sampling based on data collected in the 3 and 6 months
follow-up questionnaires will ensure a diverse range of
characteristics in terms of demographic details (age and
gender), intervention group, severity of knee condition
determined by WOMAC pain and function scores (asthis could be linked to participants’ willingness to exer-
cise), and changes in WOMAC scores after intervention
completion (as these could be linked to participants’
views about success of the BEEP interventions and lon-
ger term exercise adherence). With participants’ written
consent, interviews will be audio-recorded and tran-
scribed verbatim by professional transcribers. All tran-
scripts will be anonymised and data management and
analysis will be facilitated by NVivo (QSR International,
Version 9). Earlier interviews (at the end of physiother-
apy treatment completion) will be analysed and inform
the interview content of the interviews at the longer-
term follow-up.Statistical analyses
The trial analysis will be conducted and reported using the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines [65,69,70].Recruitment and follow-up
The number of participants identified and recruited
using each recruitment method will be reported in a
flow chart, along with the number of participants return-
ing a questionnaire at each follow-up stage. The flow
chart will include reasons for trial ineligibility and with-
drawal (when available) and will be used to compare the
recruitment success of each method to inform future
trial recruitment.
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ported for the three recruitment methods, for the three
treatment groups (to explore the effectiveness of ran-
domisation) and for those with and without data at each
follow-up time point (to explore any selective loss to
follow-up). Any differences between treatment groups
will be described by visual inspection rather than statis-
tical testing.
Primary and secondary trial analysis for clinical outcomes
The primary and secondary trial analysis will be con-
ducted blind to intervention group by the statistician
(EN) and an independent statistician will verify the ana-
lysis of the primary outcomes. The primary analysis will
compare each of the Individually Tailored Exercise and
Targeted Exercise Adherence interventions to usual physio-
therapy care on an intention-to-treat basis, for the primary
outcome at 6 months post-randomisation. Secondary ana-
lysis will include the analysis of the primary outcome at the
secondary endpoints (3, 9, 18 and 36 months) and analysis
of the secondary clinical effectiveness outcomes, as indi-
cated in Table 2, at all follow-up time points. Estimates of
clinical effect will be derived using analysis of covariance
(ANCOVA) for continuous outcome measures and logistic
regression for dichotomous outcomes and will be presented
as mean or percentage differences (as appropriate) with
95% confidence intervals after adjustment for baseline
covariates defined a priori as:
 Baseline for the outcome of interesta
 Age
 Gender
 Duration of the knee problem
 Physiotherapy treatment centre (as was used in the
randomisation algorithm)
A secondary analysis will also be completed to model
the longitudinal trajectory of WOMAC pain and func-
tion over time (the primary outcome) and the PASE
physical activity measure using generalized estimating
equations. Model predictors will include the a priori co-
variates listed above (with the baseline for the outcome
of interest modelled as a covariate rather than outcome
as recommended in Peduzzi et al [71]), time, treatment
and a time*treatment interaction. A linear model will be
fitted to the data (with time as a continuous measure)
initially, however, if the trajectory over time is non-
linear, quadratic or cubic terms will be explored. It will
also be explored that conclusions do not differ if time is
represented in the model as a categorical variable. All
model estimates will be presented with 95% confidence
intervals derived using robust standard errors.
The primary and secondary trial analyses will be con-
ducted after imputation of missing data has been completed.Missing data will be imputed using the multiple imputation
routines in STATA v11. All primary and secondary clinical
effectiveness outcomes (excluding accelerometry) and the a
priori covariates will be included in the imputation model
and will have their missing data imputed. The intention-to-
treat analysis will include participants who are protocol vio-
lators, but will not include participants who are post-
randomisation exclusions. Information on any adverse
events will be reported. We plan to analyse and publish
the results of the trial after the 18 month follow-up is
complete, and then produce a follow-up paper at
36 months.
Sensitivity analysis for clinical outcomes
The following sensitivity analyses will be completed and
reported if they change the interpretation of the findings
from the main analysis described above.
 Therapist effects: these will be explored by adding a
random effect term (to represent the treating
therapist) to the main treatment models. The
models with and without the therapist effect will be
compared at each outcome time-point to explore
the impact of the treating therapist on the effect
estimates obtained.
 Imputation of missing data: a complete case analysis
will be conducted and the results from this
compared to those from imputed data.
 Model covariates: treatment models will be run on
an unadjusted basis to investigate if the inclusion of
model covariates has an impact on the main trial
findings.
 A per protocol analysis: this will be completed on
the subsample of participants receiving treatment in
line with the specified treatment protocols. Criteria
for determining the per protocol group assignment
will be established by the Trial Management group
and approved by the Trial Steering Committee
before analysis begins.
Exploratory subgroup analysis
A set of exploratory analyses will investigate the factors
that moderate the effects of exercise in participants with
knee pain. Models will be derived using WOMAC pain
and function as the dependent variables, and intervention
group and other potentially important factors (demo-
graphic, knee-specific, exercise adherence, general health,
attitudes and outcome expectations for exercise will be
put forward as candidate independent variables). A spe-
cific subgroup analysis with strong theoretical rationale
will compare the clinical outcomes of pain and func-
tion of those who report high exercise adherence
across all intervention groups (versus those who report
lower exercise adherence). We hypothesise that those
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and function outcomes.
Analysis of adherence data
Descriptive statistics will be used to examine exercise
adherence and will be reported as numbers and percent-
ages, or means and standard deviations, as appropriate.
Exercise adherence will be measured by reporting the
number of treatment sessions attended in each treat-
ment group, and by reporting the following measures at
each follow-up time-point:
 Self-reported exercise adherence (measured by
agreement with the statement ‘I have been doing my
exercises as often as I was advised’)
 Frequency and duration of physiotherapy exercise
completed by the participant
 Change (from baseline) in level of physical activity
(measured by PASE and, in a subsample of
participants, accelerometry)
 Use of local exercise and physical activity facilities
Analysis of accelerometer data
Accelerometry data from the subsample of BEEP trial
participants will be analysed using ActiGraph (version 6)
accelerometer software. Prior to analysis, data will be
cleaned by excluding time periods containing more than
60 minutes of zero count (where it is assumed the accel-
erometer is not being worn) and by including only those
participants who have worn the accelerometer for at
least 5 days for 10 hours or more. Sensitivity analyses
will be conducted by changing the threshold to exclude
minutes of zero count from 60, to 30 and 90 minutes re-
spectively with the later threshold recommended for
participants with knee pain [72]. For each participant we
will generate the following at each data collection point:
number of valid minutes, counts per minute, proportion
of time spent at each level of physical activity, using the
cut-offs from Freedson et al [73]. We will also calculate
the proportion of participants meeting exercise/physical
activity recommendations [60].
Descriptive statistics will be given for the accelerom-
eter variables at baseline and by treatment arm. Change
(between baseline and each follow-up time point) in the
average count per minute and in the proportion meeting
the exercise recommendations will be analysed using
analysis of covariance (ANCOVA) and logistic regression
respectively with analyses adjusted for the covariates de-
fined for the clinical effectiveness analysis and by treat-
ment arm.
Economic analysis
The economic evaluation will determine the cost-
effectiveness of the two new physiotherapy-led exerciseinterventions to improve individual tailoring of, and ad-
herence to, exercise in knee OA patients in primary care,
in comparison to usual physiotherapy care. A cost-
consequence analysis will initially be reported, describing
all the important results relating to costs and conse-
quences. Subsequently, an incremental cost-utility analysis
will also be undertaken using patient responses to the EQ-
5D-3 L questionnaire to calculate the incremental cost per
additional quality-adjusted life year (QALY) gained.
Costs
Information on resource use and time off work will be col-
lected from patient-completed questionnaires at 6 months,
18 months and 36 months. Health sector costs include
primary and secondary care contacts, investigations, pain
medications and contacts with other health care profes-
sionals. The cost of the interventions will also be deter-
mined taking into account any additional resource use
required to deliver those interventions such as additional
physiotherapy visits and telephone contacts and any add-
itional equipment (e.g. pedometers) supplied to patients.
The cost of the advice and information booklet will not be
included as this will be given to all trial participants and
will therefore be cancelled out in the cost analysis. Ques-
tions on patients’ personal expenditure will concentrate
on private health care use and over-the-counter treat-
ments. Due to the lack of nationally representative unit
cost estimates for private health care, this care will be
costed as the NHS equivalent in the base-case. Patient re-
ported costs for over-the-counter treatments will be used.
Resource use will be multiplied by unit costs obtained
from standard sources and health care providers includ-
ing the British National Formulary (BNF), Unit Costs of
Health and Social Care and NHS Reference costs [74-76].
Productivity costs will be calculated using data collected
on employment status at every time point and days off
work due to knee pain. For those in paid employment, in-
formation on occupation, further details of typical work
activities and the nature of their employment (full time or
part time) will be requested. The average wage for each re-
spondent will be identified using UK Standard Occupa-
tional Classification coding [77] and annual earnings data
for each job type [78]. The analysis will use the human
capital approach, and the self-reported days of absence
will be multiplied by the respondent-specific wage rate.
The data for costs are likely to have a skewed distribu-
tion therefore the plan is to explore the nature of the
distribution of costs. If the data are not normally distrib-
uted, then a non-parametric comparison of means, using
bootstrapping, will be undertaken [79].
Health economic outcomes
All patients will be asked to complete the EQ-5D-3 L
questionnaire at baseline and at 3, 6, 9, 18 and 36 months
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time period can be calculated for each study participant,
using the area under the curve method. If differences in
baseline characteristics occur between intervention groups,
for example in baseline EQ-5D-3 L score, the analysis will
control for these baseline differences using regression-
based adjustment [80].
Cost-effectiveness analysis
The primary economic analysis will be conducted at
18 months, with additional analysis at 36 months. An
intention-to-treat analysis will be undertaken. Multiple
imputation techniques will be used to deal with missing
EQ-5D-3 L scores and resource use data, ensuring that
all eligible trial participants are included in the base case
economic evaluation. All estimates will be presented as
means with 95% confidence intervals.
The base case cost analysis will adopt a NHS and per-
sonal social services (PSS) perspective. A broader costing
perspective will be considered in a sensitivity analysis,
taking into account NHS/PSS costs, patients’ personal
expenditure and costs associated with work loss. All
costs and outcomes beyond 12 months will be dis-
counted at the standard UK rate of 3.5%.
The estimation of cost-effectiveness within this trial
will focus on the principles of dominance and extended
dominance. Dominance is a straightforward concept; if
an intervention is less effective and more costly than at
least one of its comparators, it is not included for further
consideration with regard to the estimation of cost-
effectiveness. Extended dominance is applied in incre-
mental cost-effectiveness analysis when an intervention
is less effective and more costly than a linear combin-
ation of two other strategies; the purpose is to remove
from consideration those strategies whose costs and
benefits are improved by a mixed strategy of two other al-
ternatives. The practical application of cost-effectiveness
analysis is to compare an intervention with the next most
effective strategy, therefore strategies are ordered in term
of QALYs from least to greatest. Failure to remove all
dominated or extendedly dominated strategies may lead
to comparisons that are not with the next best alternative
but with irrelevant alternatives.
The robustness of the results will be explored using
sensitivity analysis. Deterministic sensitivity analysis will
explore uncertainties in the methods employed to ana-
lyse the data, for example a complete case analysis as an
alternative to using an imputed data set, any assump-
tions made in the analysis and the generalisability of the
results to other settings.
Probabilistic sensitivity analysis (PSA) will explore the
uncertainty in the trial based data itself. Bootstrapping
will be undertaken using STATA to produce 5000 boot-
strap replications of cost-QALY difference pairs. Thesewill be plotted on a cost-effectiveness plane to illustrate
the uncertainty in the confidence to be placed on the
results of the economic analysis. This will be further
explored by estimating cost-effectiveness acceptability
curves (CEACs) [81]. These plot the probability that
the intervention is cost-effective against threshold values
for cost-effectiveness.
Finally, if one or more of the interventions demon-
strates effectiveness for the full duration of the trial, the
longer-term costs and benefits associated with that inter-
vention will be explored using decision modelling ap-
proaches to extrapolate beyond the trial follow-up.
Qualitative analyses
Data collection and analysis will be carried out iteratively
so that emerging themes in the analysis can be explored
in depth in the subsequent interviews. Earlier interviews
(at the end of physiotherapy treatment completion) with
individual participants will be analysed and inform the
interview content of the interviews at the longer-term
follow-ups. Sampling will continue until no new themes
emerge.
We will use an emergent and layered approach to ana-
lysis [82] that will allow for both induction and deduc-
tion. First, using the principles of constant comparison
[83], we will open code all transcripts. This will enable
patient experiences of the interventions, general views
on exercise and barriers and facilitators to exercise to be
explored. A researcher will code the transcribed data,
with a sample of interviews being independently coded
by other members of the research team to ensure trans-
parency and agree emergent themes at successive stages
of the data collection and analysis. Second, we will apply a
more deductive approach by re-reading transcripts and al-
locating data to predetermined codes of individualisation,
supervision and progression (three core intervention con-
structs). Third, a focused within-case and cross-case longi-
tudinal analysis will be performed by asking descriptive
and interpretative questions of the data [84]. Descriptive
questions will investigate what has changed in terms of
participants’ knee condition, adherence to the prescribed
exercise programme or general physical activity levels, and
the key influences on these changes. This will enable an
overall understanding of what is different from the first
interviews (post intervention) to the second (12 to
18 months after the end of the BEEP trial intervention)
and potential reasons for any changes. Interpretive
questions will then investigate, for example, which
changes interrelate and how these might relate to
existing theories of exercise adherence. Data summary
frameworks [82,84] will facilitate identifying patterns
of change across time. Qualitative data analysis will be
undertaken separate to the quantitative data analysis in
the first instance to facilitate an interpretative approach
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Trial organisation and monitoring
The BEEP trial is sponsored by Keele University. The
day to day operation of the trial will be overseen by a
Trial Management Group (led by NEF) and the trial will
be monitored by an independent Trial Steering Commit-
tee (TSC), chaired by Prof Michael Hurley. The TSC will
be made up of individuals with expertise in musculoskel-
etal research, exercise physiology and rheumatology. The
committee will include two lay members with osteoarth-
ritis. An independent Data Monitoring Committee (DMC)
will also monitor the study, chaired by Prof Chris Roberts.
Terms of reference for the DMC and TSC are available on
request from the BEEP trial team. During the trial period
through to 18 months follow-up, no interim analyses are
planned, unless judged necessary by the DMC. The TSC,
DMC, Trial Management Group and clinical partners will
remain ignorant of the trial results until the 18 month
follow-up data time-point.
Data confidentiality and archiving
All trial-related information will be stored securely at
the Arthritis Research UK Primary Care Centre at Keele
University. Data will be anonymised using coded identi-
fication numbers to depersonalise data with the housing
of the data and the linking code in separate locations,
under password protection. Access to the data will be to
the small number of individuals necessary for quality
control, audit and analysis. The final trial dataset will be
accessed by the statistician and the trial principal investi-
gator (NEF). We will publish and communicate the trial
results regardless of the outcome of the trial. Data from
the BEEP trial will be archived and made available for
future, secondary analysis and data pooling purposes
from the Arthritis Research UK Primary Care Centre at
Keele University.
Ethical review
The trial received research ethical approved by the North
West 1 Research Ethics Committee, Cheshire, UK (REC ref-
erence: 10/H1017/45) and site-specific approvals have been
received from the appropriate local research and develop-
ment offices, and we will provide annual reports of progress.
The trial is being conducted in accordance with the ethical
principles in the Declaration of Helsinki and good
practice guidelines on the proper conduct of research.
Discussion
The BEEP trial will compare the clinical and cost-
effectiveness of three physiotherapist-led, exercise-based
interventions, for older adults with knee pain attributable
to OA in primary care. In comparison to existing trials ofexercise for knee OA, the strengths of the BEEP trial are
its size, long-term follow-up, and inclusion of a cost-
effectiveness analysis and longitudinal qualitative inter-
views with participants. The main limitation, common to
many trials of non-pharmacological interventions, is the
inability to blind participants to treatment allocation.
The BEEP trial will inform GPs, physiotherapists, NHS
managers and service commissioners about how to opti-
mise the primary care management of older adults with
knee pain and about the resources needed to achieve it.
It will directly inform this patient group how to optimise
the benefits from exercise, inform Primary Care and
physiotherapy services about the effectiveness of their
management of knee pain in older adults and inform fu-
ture education of healthcare practitioners. It may also
help to delay and prevent some individuals from becom-
ing surgical candidates.
Endnotes
aBaseline adjustment is not relevant for the OARSI re-
sponder criteria as it incorporates baseline levels of knee
pain and function into the follow-up outcome.
Additional files
Additional file 1: BEEP trial participant information leaflet.
Additional file 2: Copy of advice booklet provided to all BEEP
participants.
Additional file 3: Copy of lower limb exercise diary.
Additional file 4: Summary of contents of adherence enhancing
tool kit.
Additional file 5: Copy of physical activity diary.
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